The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical and molecular analysis of patients treated with prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy.
 
Vincenza Conteduca
Consulting or Advisory Role - Astellas Pharma; Bayer; Janssen-Cilag; Sanofi/Aventis
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Janssen-Cilag; Sanofi/Aventis
 
Clara Oromendia
No Relationships to Disclose
 
Panagiotis J. Vlachostergios
Honoraria - Dava Oncology
 
Amy Hackett
No Relationships to Disclose
 
Charlene Thomas
No Relationships to Disclose
 
Aidan Case
No Relationships to Disclose
 
Jyothi Manohar
No Relationships to Disclose
 
Kenneth Eng
No Relationships to Disclose
 
Andrea Sboner
No Relationships to Disclose
 
Karla V. Ballman
Consulting or Advisory Role - ARIAD; Medtronic; Takeda
Patents, Royalties, Other Intellectual Property - Immune enrichment signature for response to trastuzumab in HER2+ breast cancer (Inst); Prostate cancer signature patent (Inst)
Expert Testimony - Janssen Oncology; Janssen Oncology; Lilly
 
Olivier Elemento
No Relationships to Disclose
 
David M. Nanus
Consulting or Advisory Role - Roche/Genentech
 
Himisha Beltran
Consulting or Advisory Role - Abbvie; Genzyme; GlaxoSmithKline; Janssen Oncology
Research Funding - Abbvie/Stemcentrx (Inst); Janssen (Inst); Lilly (Inst)
 
Scott T. Tagawa
Consulting or Advisory Role - Abbvie; Astellas Pharma; Bayer; Dendreon; Endocyte; Genentech; Immunomedics; Janssen; Karyopharm Therapeutics; Medivation; Sanofi; Tolmar
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Dendreon (Inst); Endocyte (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Inovio Pharmaceuticals (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Newlink Genetics (Inst); Novartis (Inst); Progenics (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Stem CentRx (Inst)
Travel, Accommodations, Expenses - Immunomedics; Sanofi